Cheonbok Fluorouracil 250mg (Fluorouracil)

Adult administration

1. Intravenous injection (systemic administration): As a monotherapy, generally, for adults, administer Fluorouracil at a dose of 5 to 15 mg/kg (not exceeding 1 g per single infusion) diluted in 300 to 500 mL of 5% dextrose injection, infused daily for 5 days. After that, administer 5 to 7.5 mg/kg via continuous intravenous infusion every other day. 2. Arterial injection: As a monotherapy, generally, for adults, administer this drug at a dose of 5 to 7.

This drug may cause serious blood disorders when used in conjunction with specific antiviral agents, so co-administration should be strictly avoided. During administration, it should be under strict supervision by a physician, and it should only be administered in a medical facility equipped for emergencies with experienced doctors. Regular liver function tests should be conducted, and attention should be paid to early symptoms of liver impairment, as liver function may be affected. Coadministration with certain combination drugs may also lead to serious blood disorders and should be avoided. Some patients, especially women who are pregnant or may become pregnant, nursing mothers, patients with severe bone marrow suppression, and those with specific enzyme deficiencies should not use this drug. Patients with poor nutritional status, liver, kidney, or heart diseases, elderly patients, and children should use this drug carefully, with special attention to adverse reactions. This drug can cause various adverse reactions affecting multiple systems such as the central nervous system, digestive system, circulatory system, blood, liver, kidneys, and skin; any symptoms should be carefully observed, and use should be discontinued immediately if problems arise. Regular blood tests and liver and kidney function tests should be performed during treatment to promptly detect and take appropriate actions for any adverse reactions. Particular attention is needed for drugs that interact with this medication, and consultations with a doctor or pharmacist about other medications being used are essential. It is preferable for women who are pregnant or nursing not to use this drug, and careful administration is also needed for children and the elderly. In case of overdose, symptoms like dizziness and movement disorders may occur, requiring immediate treatment. This drug can cause damage to the skin or blood vessels upon injection, so the injection site should be monitored closely, and administration should be discontinued if abnormalities are observed. This drug should not be mixed physically with certain chemotherapeutic agents, and caution is needed during preparation.

Serious side effects

• Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweats, pallor → severe allergic reactions
• High fever with severe rash, blisters, skin peeling, oral/eye mucosal pain → severe skin adverse reactions
• Shortness of breath or difficulty breathing, asthma attacks, cough with fever → respiratory issues
• Yellowing of the skin or eyes (jaundice), extreme malaise → liver toxicity (jaundice)
• Sudden

Mild side effects

• Central Nervous System: Fatigue, dizziness, hallucinations, memory loss, decreased spontaneity, incontinence, ataxia, tremors, speech disorders, facial paralysis, disorientation, numbness in limbs, Parkinsonian symptoms, etc.
• Gastrointestinal: Loss of appetite, nausea, vomiting, diarrhea, changes in taste, thirst, abdominal distension, abdominal pain, rectal bleeding, constipation, angular cheilitis, glossitis, stomatitis, gastrointestinal ulcers, hair loss, edema, erythema, itching, nail abnormalities, photophobia.

This medication should be stored in a sealed container to prevent contact with air, away from direct sunlight, and at room temperature between 1 to 30 degrees Celsius. Proper storage will maintain the drug's effectiveness and prevent degradation.

Appearance

A clear, colorless liquid in a colorless, transparent vial injection

Package unit

5 milliliters/vial - 5 milliliters/vial